The electrophysiology industry is anticipated to record tremendous growth by 2032. Electrophysiology (EP) tests have gained significant popularity due to the high prevalence of lifestyle-related health conditions. Due to sedentary lifestyles, excessive alcohol consumption, and tobacco smoking, the incidences of heart disease have increased considerably.

Furthermore, aging is a crucial factor in increasing the healthcare burden. Heart failure, cardiac pacing in case of bradycardia, atrial fibrillation, and ventricular arrhythmias post-myocardial infarction are some of the health conditions that require cardiac EP.

Over the last decade, the healthcare sector has witnessed substantial advancements in ablation technology, with increasing efforts to design automated, single-shot treatments for cardiac arrhythmias. The development of sophisticated 3D mapping techniques and the use of AI and machine learning will enable efficient diagnosis and treatment of cardiac diseases.

In July 2022, Stereotaxis applied for CE Marking of its MAGiC catheter, a magnetic interventional ablation catheter designed to support minimally invasive surgeries with the help of robotic navigation. Similar innovations in robotics-based cardiac ablation procedures are being led by other players such as GE Healthcare, Japan Lifeline, Medtronic, Siemens AG, and Abbott Laboratories among others.

The electrophysiology market is classified into product, indication, end-use, and region.

Based on product, the industry is bifurcated into EP diagnostic catheters, EP ablation catheters, and EP laboratory devices. The EP ablation catheters segment accounted for more than USD 2.6 billion in revenue share in 2022. The increasing geriatric population in developing countries contributing to a large patient pool of chronic diseases will propel the demand for EP ablation catheters.

By indication, the electrophysiology market share from atrial flutter is projected to reach over USD 1.7 billion by the end of 2032. Atrial flutter is a condition that occurs due to changes in the electrical system of the heart, caused by health conditions such as hypertension. According to the World Health Organization (WHO), cases of hypertension among individuals aged 30-79 years increased from 650 million to 1.28 billion over the last three decades.

With respect to end-use, the electrophysiology market is segregated into hospitals, ambulatory surgery centers, catheterization/EP laboratories, and others. The ambulatory surgery centers segment accounted for a revenue share of more than USD 180 million in 2022. Due to accessibility to advanced medical facilities, patients increasingly prefer ambulatory units for single-day cardiovascular surgeries. Ambulatory surgery centers also provide best-in-class healthcare at an affordable rate.

Asia Pacific electrophysiology market is poised to exceed USD 3.9 billion by the end of 2032. Increasing public and private funding encouraging awareness initiatives pertaining to cardiovascular diseases will complement industry expansion across APAC. Rapidly pacing medical tourism across APAC countries such as China, and India will offer lucrative business prospects over the projected timeframe.